MENU
ADAP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Adaptimmune Therapeutics (ADAP) Ownership - Who owns Adaptimmune Therapeutics?
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
60 Jubilee Avenue
Phone
+44 1235430000
Employees
449
Web
https://www.adaptimmune.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
64.94M
P/E Ratio
N/A
Total Cash
59.56M
Projected Growth
N/A
Total Debt
48.71M
Revenue
179.64M
Risk (Beta)
2.77
Dividend Yield
N/A
Total Cash/Share
0.22
Total Debt/Equity
N/A
Revenue/Share
0.70 USD as % of share price
Fundamentals
ADAP
Capitalization
64.9M
P/E Ratio
N/A
Risk (Beta)
2.77
Dividend Yield
N/A
Total Cash
59.6M
Total Cash/Share
0.22
Total Debt
48.7M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.70%
Revenue
180M
ROE
N/A
Book Value
-37.43M
P/B Ratio
5.92
Cash Flow
N/A
Earnings
-0.3
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
2.1M
Current Ratio
2.02
Current Revenue Per Employee
14397.23
Dividends Per Share - Security
N/A
EBITDA
-50.18M
Float
N/A
Float - Current
N/A
Gross Income Margin
87.93
Revenue To Assets
-33.60
Shares Held By Institutions
23.2M
Shares Outstanding - Current
265M
Total Liabilities
196M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-54.520
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a manufacturer of vaccines and cancer immunotherapy products
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Jubilee Avenue
Phone
+44 1235430000
Employees
449
Web
https://www.adaptimmune.com